Compare ENS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | BLCO |
|---|---|---|
| Founded | 1991 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Ophthalmic Goods |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | N/A | 2022 |
| Metric | ENS | BLCO |
|---|---|---|
| Price | $139.91 | $16.86 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 14 |
| Target Price | ★ $151.33 | $17.31 |
| AVG Volume (30 Days) | ★ 465.9K | 389.3K |
| Earning Date | 02-04-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 21.73 | N/A |
| EPS | ★ 8.58 | N/A |
| Revenue | $3,725,304,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $4.71 | $8.08 |
| Revenue Next Year | $2.75 | $5.77 |
| P/E Ratio | $16.87 | ★ N/A |
| Revenue Growth | 6.17 | ★ 6.23 |
| 52 Week Low | $76.57 | $10.45 |
| 52 Week High | $152.01 | $18.99 |
| Indicator | ENS | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 58.10 |
| Support Level | $145.00 | $16.83 |
| Resistance Level | $151.37 | $17.33 |
| Average True Range (ATR) | 3.78 | 0.44 |
| MACD | -1.16 | 0.01 |
| Stochastic Oscillator | 11.49 | 49.70 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.